دورية أكاديمية
أعرض في EDS

Safety and efficacy of pyronaridine-artesunate paediatric granules in the treatment of uncomplicated malaria in children: insights from randomized clinical trials and a real-world study.

التفاصيل البيبلوغرافية
العنوان: Safety and efficacy of pyronaridine-artesunate paediatric granules in the treatment of uncomplicated malaria in children: insights from randomized clinical trials and a real-world study.
المؤلفون: Ramharter M; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.; German Centre for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel, Hamburg, Germany.; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon., Djimde AA; Malaria Research and Training Center (MRTC), Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali., Borghini-Fuhrer I; Medicines for Malaria Venture, Route de Pré-Bois 20, 1215, Geneva 15, Switzerland., Miller R; Artemida Pharma, Stevenage, UK., Shin J; Shin Poong Pharm. Co. Ltd, Seoul, Korea., Aspinall A; Medicines for Malaria Venture, Route de Pré-Bois 20, 1215, Geneva 15, Switzerland., Richardson N; Magenta Communications Ltd, Abingdon, UK., Wibberg M; DATAMAP GmbH, Freiburg, Germany., Fleckenstein L; Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, USA., Arbe-Barnes S; Artemida Pharma, Stevenage, UK., Duparc S; Medicines for Malaria Venture, Route de Pré-Bois 20, 1215, Geneva 15, Switzerland. duparcs@mmv.org.
المصدر: Malaria journal [Malar J] 2024 Feb 28; Vol. 23 (1), pp. 61. Date of Electronic Publication: 2024 Feb 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101139802 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2875 (Electronic) Linking ISSN: 14752875 NLM ISO Abbreviation: Malar J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2002-
مواضيع طبية MeSH: Antimalarials*/adverse effects , Artemisinins*/adverse effects , Malaria, Falciparum*/drug therapy , Malaria*/drug therapy , Artesunate* , Naphthyridines*, Child ; Humans ; Artemether, Lumefantrine Drug Combination/therapeutic use ; Artemether/therapeutic use ; Randomized Controlled Trials as Topic ; Drug Combinations ; Treatment Outcome ; Vomiting/chemically induced ; Vomiting/drug therapy ; Ethanolamines/therapeutic use
مستخلص: Background: Children are particularly at risk of malaria. This analysis consolidates the clinical data for pyronaridine-artesunate (PA) paediatric granules in children from three randomized clinical trials and a real-world study (CANTAM).
Methods: An integrated safety analysis of individual patient data from three randomized clinical trials included patients with microscopically-confirmed Plasmodium falciparum, body weight ≥ 5 kg to < 20 kg, who received at least one dose of study drug (paediatric safety population). PA was administered once daily for 3 days; two trials included the comparator artemether-lumefantrine (AL). PCR-adjusted day 28 adequate clinical and parasitological response (ACPR) was evaluated. Real-world PA granules safety and effectiveness was also considered.
Results: In the integrated safety analysis, 63.9% (95% CI 60.2, 67.4; 426/667) of patients had adverse events following PA and 62.0% (95% CI 56.9, 66.9; 222/358) with AL. Vomiting was more common with PA (7.8% [95% CI 6.0, 10.1; 52/667]) than AL (3.4% [95% CI 1.9, 5.8; 12/358]), relative risk 2.3 (95% CI 1.3, 4.3; P = 0.004), occurring mainly following the first PA dose (6.7%, 45/667), without affecting re-dosing or adherence. Prolonged QT interval occurred less frequently with PA (3.1% [95% CI 2.1, 4.8; 21/667]) than AL (8.1% [95% CI 5.7, 11.4; 29/358]), relative risk 0.39 (95% CI 0.22, 0.67; P = 0.0007). In CANTAM, adverse events were reported for 17.7% (95% CI 16.3, 19.2; 460/2599) of patients, most commonly vomiting (5.4% [95% CI 4.6, 6.4; 141/2599]), mainly following the first dose, (4.5% [117/2599]), with all patients successfully re-dosed, and pyrexia (5.4% [95% CI 4.6, 6.3; 140/2599]). In the two comparative clinical trials, Day 28 ACPR in the per-protocol population for PA was 97.1% (95% CI 94.6, 98.6; 329/339) and 100% (95% CI 99.3, 100; 514/514) versus 98.8% (95% CI 95.7, 99.9; 165/167) and 98.4% (95% CI 95.5, 99.7; 188/191) for AL, respectively. In CANTAM, PA clinical effectiveness was 98.0% (95% CI 97.3, 98.5; 2273/2320).
Conclusions: Anti-malarial treatment with PA paediatric granules administered once daily for 3 days was well tolerated in children and displayed good clinical efficacy in clinical trials, with effectiveness confirmed in a real-world study. Trial registration Clinicaltrials.gov: SP-C-003-05: identifier NCT00331136; SP-C-007-07: identifier NCT0541385; SP-C-021-15: identifier NCT03201770. Pan African Clinical Trials Registry: SP-C-013-11: identifier PACTR201105000286876.
(© 2024. The Author(s).)
References: Antimicrob Agents Chemother. 2015 Dec 14;60(3):1450-8. (PMID: 26666916)
Lancet. 2018 Apr 7;391(10128):1378-1390. (PMID: 29606364)
N Engl J Med. 2012 Apr 5;366(14):1298-309. (PMID: 22475593)
Lancet Glob Health. 2020 Dec;8(12):e1499-e1511. (PMID: 33222799)
PLoS Med. 2021 Jun 15;18(6):e1003669. (PMID: 34129601)
Malar J. 2023 Dec 5;22(1):371. (PMID: 38053100)
Lancet Infect Dis. 2016 Feb;16(2):189-98. (PMID: 26601738)
Lancet Infect Dis. 2010 Feb;10(2):125-32. (PMID: 20113981)
Lancet. 2010 Apr 24;375(9724):1457-67. (PMID: 20417857)
J Infect Dis. 2008 Sep 15;198(6):911-9. (PMID: 18694333)
Cochrane Database Syst Rev. 2019 Jan 08;1:CD006404. (PMID: 30620055)
PLoS One. 2011 Jan 18;6(1):e14501. (PMID: 21267072)
Malar J. 2022 Jan 4;21(1):4. (PMID: 34983552)
Malar J. 2018 May 15;17(1):199. (PMID: 29764419)
Malar J. 2013 Feb 21;12:70. (PMID: 23433102)
Malar J. 2012 Oct 31;11:364. (PMID: 23113947)
فهرسة مساهمة: Keywords: Plasmodium falciparum; Anti-malarial; Granule formulation; Malaria; Paediatric; Pyronaridine–artesunate
سلسلة جزيئية: ClinicalTrials.gov NCT00331136; NCT0541385; NCT03201770
المشرفين على المادة: 0 (pyronaridine tetraphosphate, artesunate drug combination)
0 (Antimalarials)
0 (Artemether, Lumefantrine Drug Combination)
0 (Artemisinins)
C7D6T3H22J (Artemether)
0 (Drug Combinations)
0 (Ethanolamines)
60W3249T9M (Artesunate)
0 (Naphthyridines)
تواريخ الأحداث: Date Created: 20240228 Date Completed: 20240301 Latest Revision: 20240302
رمز التحديث: 20240302
مُعرف محوري في PubMed: PMC10902982
DOI: 10.1186/s12936-024-04885-3
PMID: 38418982
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-2875
DOI:10.1186/s12936-024-04885-3